Low recurrence rate of hepatocellular carcinoma following ledipasvir and sofosbuvir treatment in a real-world chronic hepatitis c patients cohort

Basit Öğe Kaydı
dc.contributor.authorIdilman, Ramazan
dc.contributor.authorDemir, Mehmet
dc.contributor.authorAladag, Murat
dc.contributor.authorErol, Cihan
dc.date.accessioned2019-06-19T08:33:00Z
dc.date.available2019-06-19T08:33:00Z
dc.date.issued2018
dc.departmentİnönü Üniversitesien_US
dc.description.abstractThe aims of the present study were to evaluate the efficacy and tolerability of ledipasvir/sofosbuvir (LDV/SOF) with or without ribavirin in the treatment of chronic hepatitis C (CHC) in patients with advanced liver disease and to analyse whether the use of LDV/SOF treatment is associated with a new occurrence of hepatocellular carcinoma (HCC) during and after LDV/SOF treatment. The Turkish Early Access Program provided LDV/SOF treatment to a total of 200 eligible CHC patients with advanced liver disease. The median follow-up period was 22months. All patients were Caucasian, 84% were infected with genotype 1b, and 24% had a liver transplantation before treatment. The sustained virological response (SVR12) was 86.0% with ITT analysis. SVR12 was similar among patients with Child-Pugh classes A, B and C disease and transplant recipients. From baseline to SVR12, serum ALT level and MELD score were significantly improved (P<0.001). LDV/SOF treatment was generally well tolerated. Only one patient developed a new diagnosed HCC. Seventeen of the 35 patients, who had a history of previous HCC, developed HCC recurrence during the LDV/SOF treatment or by a median follow-up of 6months after treatment. HCC recurrence was less commonly observed in patients who received curative treatment for HCC compared with those patients who received noncurative treatment (P=0.007). In conclusion, LDV/SOF with or without ribavirin is an effective and tolerable treatment in CHC patients with advanced liver disease. Eradication is associated with improvements in liver function and a reduced risk of developing a new occurrence of HCC. Ledipasvir and sofosbuvir with or without ribavirin is an effective and tolerable treatment in hepatitis C virus-infected patients with advanced liver disease. Eradication is associated with improvements in liver function and reduces the risk of developing a new occurrence of hepatocellular carcinoma.en_US
dc.identifier.citationIdilman, R. Demir, M. Aladag, M. Erol, C.(2018). Low recurrence rate of hepatocellular carcinoma following ledipasvir and sofosbuvir treatment in a real-world chronic hepatitis c patients cohort.Cilt:26. Sayı:6 666-674ss.en_US
dc.identifier.doi10.1111/jvh.13075en_US
dc.identifier.endpage674en_US
dc.identifier.issue6en_US
dc.identifier.startpage666en_US
dc.identifier.urihttps://hdl.handle.net/11616/11461
dc.identifier.volume26en_US
dc.language.isoenen_US
dc.publisherJournal of vıral hepatıtısen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectcirrhosisen_US
dc.subjectdirect-acting antiviralsen_US
dc.subjecthepatitis C virusen_US
dc.subjecthepatocellular carcinomaen_US
dc.subjectliver transplantationen_US
dc.titleLow recurrence rate of hepatocellular carcinoma following ledipasvir and sofosbuvir treatment in a real-world chronic hepatitis c patients cohorten_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
MAKALE DOSYASI.pdf
Boyut:
93.75 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Makale dosyası
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.71 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Tıp Fakültesi, İç Hastalıkları Anabilim Dalı Koleksiyonu